US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Tourmaline Bio Inc
NASDAQ:TRML
Tourmaline Bio Inc
Operating Income
Tourmaline Bio Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tourmaline Bio Inc
NASDAQ:TRML
|
Operating Income
-$45.4m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
See Also
What is Tourmaline Bio Inc's Operating Income?
Operating Income
-45.4m
USD
Based on the financial report for Dec 31, 2023, Tourmaline Bio Inc's Operating Income amounts to -45.4m USD.
What is Tourmaline Bio Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-26%
Over the last year, the Operating Income growth was 40%. The average annual Operating Income growth rates for Tourmaline Bio Inc have been -26% over the past three years .